# Sonoma Pharmaceuticals (SNOA) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/SNOA
## Company Profile
- Ticker: SNOA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 1.13 USD
- Market cap: 4029322.6399999997 USD
- Last updated: 2026-08-05
## Business Overview
### Hypochlorous Acid Medical Products
Sonoma Pharmaceuticals develops and manufactures stabilized hypochlorous acid products for wound care, eye care, nasal care, oral care, dermatology, podiatry, animal health, and non-toxic disinfection.
### Microcyn Technology
The company’s Microcyn technology produces safe and stable HOCl formulations. The products are intended to reduce itching, pain, scarring, and irritation without damaging healthy tissue and are used in applications including minor abrasions, cuts, and intact-skin management.
### Broad End-Market Portfolio
Sonoma adapts the same stabilized HOCl technology across human and animal healthcare. This creates a product portfolio serving wound care, dermatology, eye and nasal care, oral care, podiatry, animal health, and non-toxic disinfection.
### Global Commercial Network
Sonoma products are sold directly or through partners in more than 55 countries. The company has recently expanded its U.S. product lineup and channel relationships, including the manufacture of a new HOCl wound cleanser for Medline.
## Why The Stock Is Moving

The latest monitored company update is “Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- Sonoma’s catalysts are wound-care and skin-health product demand, along with any update that clarifies the commercial path. The business moves on product adoption.

## Recent News
- 2026-08-06 13:00 EST — [Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA](https://biopharmsignal.com/news/SNOA/sonoma-pharmaceuticals-delivers-141-u-s-revenue-growth-in-fy-q1-60-total-revenue-637c5159) — Source: Sonoma Pharmaceuticals
- 2026-06-30 13:00 EST — [Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution](https://biopharmsignal.com/news/SNOA/sonoma-pharmaceuticals-receives-fda-510-k-clearance-expanding-indications-and-pa-421ff719) — Source: Sonoma Pharmaceuticals
- 2026-06-16 20:15 EST — [Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results](https://biopharmsignal.com/news/SNOA/sonoma-pharmaceuticals-reports-fiscal-year-and-fourth-quarter-2026-financial-res-04e8ed16) — Source: Sonoma Pharmaceuticals
- 2026-04-24 13:21 EST — [Sonoma Pharmaceuticals Announces Pricing of $4 Million Public Offering](https://biopharmsignal.com/news/SNOA/sonoma-pharmaceuticals-announces-pricing-of-4-million-public-offering) — Source: Sonoma Pharmaceuticals
- 2026-03-24 12:30 EST — [Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart](https://biopharmsignal.com/news/SNOA/sonoma-pharmaceuticals-announces-u-s-retail-launch-of-advanced-burn-relief-hydrogel-in-cvs-and-walmart) — Source: Sonoma Pharmaceuticals